• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

MOU 225-98-8000

Memorandum of Understanding

Between
The Food and Drug Administration 

and

The Indian Health Service

 

I. PURPOSE

The Food and Drug Administration (FDA) and the Indian Health Service (IHS), U.S. Department of Health and Human Services (DHHS), have mutual interests in fostering improved health care and access to policy and education programs.

FDA and IHS intend to work to develop a more cohesive relationship to mutually address American Indian and Alaska Native issues within the context of each organization's jurisdiction. FDA and IHS agree to work together to promote and support appropriate ongoing DHHS and organizationally specific initiatives, such as:

 

Collaborative Tribal Consultations
-- National Congress of American Indians
-- National Indian Health Board
-- Regional Health Boards

The White House Initiative on Tribal Colleges and Universities

Expert Technical Assistance

Collaborative Public Health Education Campaigns
-- Tobacco
-- Clinical Trials and Education
-- Women's Health Issues – (Urban and Rural)
-- "Take Time to Care" Campaign
-- Food Labeling Education
-- Food/Nutrient/Deficiency/Food supplementation issues for women of child bearing age and health professionals
-- Food Safety Initiative
-- Health Fraud

Collaborative Consumer Studies

Collaborative Recruitment

This MOU establishes policies and principles by which the parties may be guided when executing specific interagency agreements for the exchange of funds, services, or personnel.

II. AUTHORITY

Food and Drug Administration: Section 903 of the FFDCA (21 U.S.C. 393), Section 301 of the PHSA, (42 U.S.C. 241), Sections 1701 et seq. of the PHSA (42 U.S.C. 300u et seq.)

Indian Health Service: Transfer Act (42 U.S.C. 2001) of 1954.

 

III. BACKGROUND

The FDA and the IHS have been independently conducting activities, in the context of their jurisdictions, to improve the knowledge base of American Indian and Alaska Native populations and to involve these individuals in their respective processes. The FDA and the IHS recognized that the success of those efforts can be enhanced by greater collaboration.

The IHS has focused its outreach activities primarily on the needs of American Indian and Alaska Native populations. Similarly, the FDA has focused its efforts primarily upon the needs of the general population with intermittent emphasis upon American Indian and Alaska Native populations.

The goal of the FDA and the IHS collaborations will be to accomplish the following:

(1) More effectively interface with the IHS, the National Indian Health Board, the National Congress of American Indians, Regional Health Boards, and other DHHS components by:

--soliciting tribal advice and recommendations on approaches to achieve appropriate levels of effective and efficient involvement of American Indians and Alaska Natives in the FDA's regulatory and outreach processes;

--Enhancing local consultations and collaborations with tribal governments, when appropriate;

--receiving assistance in improving involvement of American Indians and Alaska Natives in Agency policy initiatives;

--discussing collaborative approaches to promote the safe and practical use of FDA-regulated products among American Indian and Alaska Native populations;

--discussing approaches and establishing distribution systems for materials through IHS Tribal and Urban Indian Health Programs, Indian schools, community colleges and universities, IHS Medical Centers and the Department of Veterans Affairs' regional medical centers;

(2) Improve access of American Indians and Alaska Natives to FDA generated information on health risks and policy issues;

(3) provide community based organizations and concerned individuals with the opportunities to have appropriate input into regulatory processes such as;

--encourage participation of American Indians and Alaska Natives in Agency-sponsored conferences, meetings, focus groups, and consumer studies;

--promote opportunities to serve on the FDA's advisory committees and panels, science boards, and in research;

(4) provide FDA and IHS officials and managers with the perspectives on America Indian and Alaska Native health care and education needs and policy issues;

(5) promote diversity in the planning and application of existing educational programs and services that encourage youth to pursue careers in the sciences, math, and other disciplines that may lead to careers in the advanced sciences, engineering and the health professions; and

(6) continue recruitment efforts to American Indian and Alaska Native populations through programs such as the Cooperative Education Programs (CO-OP), Commissioned Officer Student Training and Extern Program (COSTEP), fellowships, personnel exchanges, and summer employment programs through Tribal Colleges and Universities and professional associations.

 

IV. SCOPE OF WORK

The FDA and the IHS hereby express their firm intentions to jointly address American Indian and Alaska Native issues within the context of regulatory processes and programs conducted by the FDA primarily for the general U.S. population, as resources permit. Given the diversity of education, knowledge, understanding and cultures within the American Indian and Alaska Native populations, the IHS will work with FDA to enhance its activities with American Indian and Alaska Native populations.

FDA and IHS have established formal liaisons for both Agencies that will foster an information exchange on all aspects of the MOU. Other functions of the Agency liaisons may include the following:

Work with intra/inter-agency task groups to identify the type of technical assistance and outreach necessary to provide American Indian and Alaska Native populations with information and education.

Exchange information on currently funded programs that have objectives to address the health education needs of American Indian and Alaska Native populations.

Review opportunities for mutual and flexible funding and cooperative extension of funded programs for American Indian and Alaska Native populations through FDA and IHS grant programs.

Strengthen mutual cooperative activities and technical support in working with other DHHS components in developing resources to collect improved statistics on American Indian and Alaska Native populations. 

V. DURATION OF AGREEMENT

This MOU will become effective upon acceptance by both parties and will continue in effect indefinitely. This MOU may be modified by mutual written consent or terminated by either party upon 60 day advance notice to the other party.

VI. LIAISONS/PROJECT OFFICERS

U.S. FOOD AND DRUG ADMINISTRATION
 
Mary C. Hitch,
Senior Policy Advisor
FDA Tribal Liaison
Office of Health and Constituent Affairs
Office of External Affairs
10903 New Hampshire Avenue, Room 5320
Silver Spring, M.D. 20993
301-796-8639
 
INDIAN HEALTH SERVICE
 
Carl Harper, Director
Office of Resource Access and Partnerships
12300 Twinbrook Parkway, Suite 360
Rockville, MD 20852
301-443-1553

INDIAN HEALTH SERVICE
AREA DIRECTORS 

Aberdeen Area Office
115 4th Aenue, SD 57401
 
Alaska Area Office
4141 Ambassador Drive, Suite 300
Anchorage, AK 99508
 
Albuquerque Area Office
5300 Homestead Drive N.E.
Albuquerque, NM87110
 
Bemidji Area Office
522 Minnesota Ave., N.W.
Bemidji, MN 56601
 
Billings Area Office
2900 4th Avenue North
Billings, MT 59101
 
California Area Office
650 Capitol Mall, Suite 7-100
Sacramento, CA 95814
 
Nashville Area Office
711 Stewarts Ferry Pike
Nashville, TN 37214
 
Navajo Area Office
P.O. Box 9020
Window Rock, AZ 86515
 
Oklahoma Area Office
701 Market Drive
Oklahoma City, OK 73114
 
Phoenix Area Office
Two Renaissance Square
40 North Central Avenue, Suite 600
Phoenix, AZ 854004-4450
 
Portland Area Office
1414 NW Northrup Street, Suite 800
Portland, OR 97209
 
Tucson Area Office
7900 South J Stock Road
Tucson, AZ 85746

 

Approved and Accepted
for the Indian Health Service

Signed by: Director, Indian Health Service

Date: July 9, 1997

 

Approved and Accepted
for the Food and Drug Administration

Signed by: Lead Deputy Commissioner
Food and Drug Administration

Date: July 9, 1997